Novartis’ Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie’s Humira
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix Global Insights. [Exton, PA., January 10, 2024] — In late October 2023, the FDA granted approval to Novartis’ Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the second biologic approved alongside AbbVie’s Humira […]
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of plaque psoriasis. Exton, PA., December 7, 2023 – While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call, practicing dermatologists in Spherix research highlight […]
Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according to a recent analysis (Market Dynamix: Alopecia Areata). Additionally, more than half of US dermatologists have begun trial of ritlecitinib (Litfulo; Pfizer) in their patients with AA. According to the analysis, 6-month market projections for […]
Eli Lilly’s Olumiant and Pfizer’s Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market lead over Litfulo. [Exton PA, November 15, 2023] — Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK inhibitors has […]
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]
Amgen tipped to keep Otezla market share in fight with BMS’ Sotyktu, leaving opportunity for J&J
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. BMS sold Otezla to Amgen to secure regulatory clearance for […]
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring enhanced safety and efficacy. Exton, PA August 31, 2023 – The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent autoimmune history. With the entry […]
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton, PA, July 11, 2023 – In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata (AA). At one-year post approval, perceptions of the […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such as AbbVie, Amgen, Eli Lilly, Janssen, and Novartis could have a competitive edge over more novel developers. EXTON, Pa., March 17, 2020 /PRNewswire/ — The past decade has ushered in an array of new treatment […]
